1541 Stock Overview
A biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.67 |
| 52 Week High | HK$31.50 |
| 52 Week Low | HK$3.21 |
| Beta | 0 |
| 11 Month Change | 0.18% |
| 3 Month Change | -56.38% |
| 1 Year Change | -79.53% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -70.95% |
Recent News & Updates
Shareholder Returns
| 1541 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -13.7% | -4.4% | -4.3% |
| 1Y | -79.5% | -1.9% | 15.6% |
Return vs Industry: 1541 underperformed the Hong Kong Biotechs industry which returned -1.9% over the past year.
Return vs Market: 1541 underperformed the Hong Kong Market which returned 15.6% over the past year.
Price Volatility
| 1541 volatility | |
|---|---|
| 1541 Average Weekly Movement | 25.3% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.7% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 1541's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1541's weekly volatility has increased from 17% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 150 | Tian Wenzhi | www.immuneonco.com |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China. Its core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors. It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase I clinical trial to treat solid tumors; IMM2520, which is in Phase I clinical trial for solid tumors; IMM2902 that in Phase I clinical trial for the treatment of HER2-positive and low expressing solid tumors; and IMM47 for the treatment of advanced malignant and solid tumors, and R/R B-NHL.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Fundamentals Summary
| 1541 fundamental statistics | |
|---|---|
| Market cap | HK$2.01b |
| Earnings (TTM) | -HK$408.67m |
| Revenue (TTM) | HK$7.96m |
266.6x
P/S Ratio-5.2x
P/E RatioIs 1541 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1541 income statement (TTM) | |
|---|---|
| Revenue | CN¥7.29m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥7.29m |
| Other Expenses | CN¥381.68m |
| Earnings | -CN¥374.39m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.00 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,135.65% |
| Debt/Equity Ratio | 14.3% |
How did 1541 perform over the long term?
See historical performance and comparison